Cochrane · systematic review · CD007216
Tacrolimus (FK506) for induction of remission in corticosteroid‐refractory ulcerative colitis
Gordon, M, Sinopoulou, V, Akobeng, AK, et al. · Cochrane Database of Systematic Reviews · 2022 · Cochrane Library
GutAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
12
current version
GRADE rated
10
No studies
2
Included studies
NR
No studies 2 · 16.7%Ungraded 0 · 0%Very low 3 · 25%Low 7 · 58.3%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Tacrolimus compared to placebo for induction of clinical remission in refractory ulcerative colitis
Population: adults with refractory, moderate‐to‐severe ulcerative colitis
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Clinical remission Tacrolimus vs placebo | RR 3.76 [1.03, 13.73] | 3 studies · 148 participants | Low Downgraded: risk of bias, imprecision |
Clinical improvement Tacrolimus vs placebo | RR 4.47 [2.15, 9.29] | 3 studies · 148 participants | Low Downgraded: risk of bias, imprecision |
Serious adverse events Tacrolimus vs placebo | RR 2.44 [0.12, 48.77] | 3 studies · 148 participants | Very low Downgraded: imprecision |
Total adverse events Tacrolimus vs placebo | RR 1.18 [0.91, 1.54] | 3 studies · 148 participants | Low Downgraded: risk of bias, imprecision |
Tacrolimus compared with ciclosporin for induction of remission in refractory ulcerative colitis
Population: adults with refractory, moderate‐to‐severe ulcerative colitis
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Clinical remission Tacrolimus vs ciclosporin | RR 1.52 [0.92, 2.5] | 1 study · 113 participants | Very low Downgraded: risk of bias, imprecision |
Clinical improvement Tacrolimus vs ciclosporin | RR 0.9 [0.7, 1.16] | 1 study · 113 participants | Very low Downgraded: risk of bias, imprecision |
Serious adverse events Tacrolimus vs ciclosporin | no estimate extracted | NR | No studies |
Total adverse events Tacrolimus vs ciclosporin | no estimate extracted | NR | No studies |
Tacrolimus compared with beclometasone for induction of remission in refractory ulcerative colitis
Population: adults with refractory, moderate‐to‐severe ulcerative colitis
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Clinical remission Tacrolimus vs beclometasone | RR 1.07 [0.6, 1.88] | 1 study · 88 participants | Low Downgraded: imprecision |
Clinical improvement Tacrolimus vs beclometasone | RR 1 [0.66, 1.52] | 1 study · 88 participants | Low Downgraded: imprecision |
Serious adverse events Tacrolimus vs beclometasone | RR 3 [0.13, 71.7] | 1 study · 88 participants | Low Downgraded: imprecision |
Total adverse events Tacrolimus vs beclometasone | RR 1.5 [0.88, 2.55] | 1 study · 88 participants | Low Downgraded: imprecision |